Stockscreener 앱 받기
8.82
25.46%
1.79
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
Vanda Pharmaceuticals Says FDA Will Take More Time To Decide On Tradipitant Clinical Hold Re-Review - MSN
Vanda wins FDA approval for NEREUS motion sickness drug - MSN
Vanda stock jumps with FDA approval of motion sickness drug - BioWorld MedTech
Vanda Pharmaceuticals hits 3-year high after FDA approves Nereus | Tap to know more | Inshorts - Inshorts
US FDA approves Vanda Pharmaceuticals' motion sickness drug - Reuters
D.C.-based Vanda gets FDA nod for motion-sickness treatment - The Business Journals
What's Going On With Vanda Pharmaceuticals Stock Wednesday? - Benzinga
Vanda Pharmaceuticals: Could Now Be A Good Time To Invest? - StocksToTrade
Vanda surges 28% after FDA approval - breakingthenews.net
B. Riley Securities Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Raises Target Price to $14 - 富途牛牛
B. Riley Securities Raises Price Target for VNDA to $14.00 Maint - GuruFocus
Vanda Pharmaceuticals price target raised to $14 from $11 at B Riley - MSN
Vanda Pharmaceuticals Inc. (VNDA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vanda Pharmaceuticals (NASDAQ:VNDA) Hits New 52-Week HighHere's What Happened - MarketBeat
Vanda Pharma's (VNDA) NEREUS Approval Boosts Growth Prospects - GuruFocus
Vanda Jumps 21% After FDA Approves Motion Sickness Therapy - GuruFocus
Vanda Pharmaceuticals Stock Jumps After FDA Approves Motion Sickness Drug - Barron's
Vanda Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals price target raised to $7.50 from $5 at Jefferies - TipRanks
Biggest Mover Wednesday: Vanda's FDA Win Sends the Stock Flying - GuruFocus
Biggest stock movers Wednesday: Vanda Pharmaceuticals and Cybin - MSN
Vanda Pharmaceuticals Stock Rockets: Time to Ride the Wave? - timothysykes.com
FDA approves Vanda Pharmaceuticals’ motion sickness drug Nereus - Pharmaceutical Technology
Vanda Pharmaceuticals (VNDA) Surges 21% on FDA Approval of Motion Sickness Drug - GuruFocus
Vanda Pharmaceuticals stock soars after FDA approval of motion sickness drug - Investing.com
VNDA: Jefferies Maintains Hold Rating, Raises Price Target to $7.50 | VNDA Stock News - GuruFocus
B. Riley Raises Price Target on Vanda Pharmaceuticals to $14 Form $11, Keeps Buy Rating - marketscreener.com
Vanda Pharmaceuticals surges as FDA approves motion sickness drug - Sharecast.com
Market news - investments.halifax.co.uk
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains - Yahoo Finance
Vanda Pharmaceuticals (VNDA) Gains FDA Nod for Motion Sickness D - GuruFocus
Stock Movers: VANDA PHARMACEUTICALS , NIKE , SPX - Bloomberg.com
Vanda Wins FDA Approval for NEREUS Motion Sickness Drug - TipRanks
Jefferies raises Vanda Pharmaceuticals stock price target on motion sickness drug potential - Investing.com
Why Is VNDA Stock Surging Premarket? FDA Approves Motion Sickness Drug - Tokenist
Vanda Pharmaceuticals (VNDA) Surges on FDA Approval - GuruFocus
FDA Greenlights Vanda Pharmaceuticals' (VNDA) New Motion Sicknes - GuruFocus
Vanda Pharmaceuticals (VNDA) Shares Surge Following FDA Approval - GuruFocus
Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades - ts2.tech
Trending tickers: latest investor updates on Nvidia, Caterpillar, Vanda Pharmaceuticals and Walker Crips - Yahoo Finance UK
Stock Market Today: S&P 500, Dow Jones Futures Down As Santa Rally Hopes Fade—Investors Await Initial Jobless Claims Report - Benzinga
US FDA approves Vanda Pharmaceuticals’ motion sickness drug - WTVB
Why Is Vanda Pharmaceuticals' (VNDA) Stock Trending Overnight? - Benzinga
US FDA approves Vanda Pharmaceuticals’ motion sickness drug By Reuters - Investing.com
US FDA Approves Vanda Pharmaceuticals' Motion Sickness Drug - U.S. News & World Report
Vanda Pharmaceuticals announces FDA approval of Nereus (tradipitant) - marketscreener.com
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness - Nasdaq
3 Biotech Stocks With Major 2026 Catalysts - Yahoo Finance
The Christmas party is still ongoing in these stocks: Nvidia, Sidus Space, Coupang, Vanda Pharmaceuticals, ImmuCell - MSN
The Christmas Party Is Still Ongoing In These Stocks: Nvidia, Sidus Space, Coupang, Vanda Pharmaceuticals, ImmuCell - Asianet Newsable
Vanda’s FDA Moment: A High-Stakes Bet That Could Redefine The Stock - Stocktwits
Vanda Pharmaceuticals Stock Rallies on FDA Filing - Schaeffer's Investment Research
Vanda Pharmaceuticals (STU:VM4) EV-to-OCF : -1.36 (As of Dec. 21, 2025) - GuruFocus
Will Vanda Pharmaceuticals Inc. stock outperform tech sector in 2025Quarterly Portfolio Report & Accurate Entry/Exit Alerts - Улправда
0.90%
자본화:
|
볼륨(24시간):